Immunotech Biopharm expects to collect results from its clinical trials on liver-cancer patients next year and aims to win marketing approval for its technology in 2022, CEO Wang Yu says.
( read original story …)
The Japan News
Immunotech Biopharm expects to collect results from its clinical trials on liver-cancer patients next year and aims to win marketing approval for its technology in 2022, CEO Wang Yu says.
( read original story …)